Fengchao Pharmaceutical Technology (Shanghai) Co., Ltd., established on 2015-08-11, The scope of business includes engaging in medical technology,Biological Technology,Ecotechnology,Chemical Technology,New Material Technology,Technology development in the field of new energy technology,technical consulting,Technical Services,technology transfer,Industrial Investment.[Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Ciba-Geigy AG was manufacturing pharmaceuticals. The company was merged with Sandoz Ltd. to create Novartis AG. The company was founded in 1884 and was headquartered in Basle, Switzerland.

GestVision, Inc. is commercializing a point of care diagnostic test for preeclampsia. The pregnancy-related condition is often characterized by the symptoms of high blood pressure and protein in the urine. Left untreated, the condition can lead to seizures and even death. Preeclampsia is an equal opportunity problem and is of concern in both developed and developing nations. The US is not immune and sees preeclampsia as a growing problem.

Hangzhou Berry Hekang Gene Diagnostic Technology Co., Ltd., established on 2011-09-06, Business scope includes production:third category6840In vitro diagnostic reagents,third category6840Clinical Laboratory Analytical Instruments,second category6870software;technology development,Technical Services:genetic diagnosis technology,Biotechnology,Chemical Products(Removal of hazardous chemicals and precursor chemicals);wholesale,retail:electronic product,Daily necessities,Laboratory equipment,laboratory consumables,biological reagent(Except for projects involving pre-approval);Import and export of goods and technology(law,Except for items prohibited by administrative regulations,law,Projects that are restricted by administrative regulations can only be operated after obtaining a license).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Glaxo Group Ltd. operates through its subsidiary Glaxo Laboratories Ltd. that engages in the production of food products for infants such as Ostermilk, Complan, Casilan, Farex. Glaxo Group Ltd. was formerly known as Glaxo Laboratories Ltd. and changed its name to Glaxo Group Ltd. in 1962. The company is based in Brentford, United Kingdom. Glaxo Group Ltd. operates as a subsidiary of Glaxosmithkline plc.

Toray Industries, Inc. (東レ株式会社 Tōre Kabushiki-gaisha) is a multinational corporation headquartered in Japan that specializes in industrial products centered on technologies in organic synthetic chemistry, polymer chemistry, and biochemistry.

CAVΛDIS™ is a Dutch biomedical company active in the field of cardiovascular risk assessment. They develop prognostic tests to identify patients at risk of cardiovascular and disease. The company identified several novel biomarkers predictive for cardiovascular events. It is their goal is to develop clinically meaningful risk stratification tools that will help personalize treatment and achieve better patient outcomes.

ITI Scotland Ltd. is a company set up in 2003 by Scottish Enterprise with the support of the Scottish Executive to identify and commercialise valuable technology-based intellectual assets across three global market sectors: digital media and communications; life sciences and energy.

NeoCura provides an AI platform to collect and analyze molecular biology data and clinical data, enabling physicians to make improve the diagnosis and treatment of cancer patients.

Tencent Technology (Shenzhen) Co., Ltd. designs and develops computer software and provides Internet information services in China. It offers instant messaging services; QQ, an Internet-based instant messaging tool to support online message communications and instant voice, video, and file transmission; TM, an instant messaging communication software application; Real Time eXchange, an instant messaging platform launched for enterprises; Traveler, a multi-page web page browser; QQDoctor, an anti-virus tool developed to address the problem of Trojan viruses that steal QQ passwords; QQMailbox, provides e-mail services to users; and QQDownload, software that simultaneously supports various download tasks. The company was founded in 2000 and is located in Shenzhen, China.

Part of University of Toronto, The Governing Council of the University of Toronto is a Canadian company located in Toronto, ON, focused on colleges, universities, and professional schools.

Pierre Fabre Médicament SA manufactures cosmetics and pharmaceutical products. It focuses on research, development, and prescription of medicines and cosmetics. The company was founded on December 31, 1982 and is headquartered in Boulogne-Billancourt, France.

Nanjing Chengshi Biomedical Technology Co., Ltd., established on 2019-07-19, Business scope includes biotechnology extension services;medical research and trials;Biomedical Technology Research;drug development;pharmaceutical research;Biotechnology Transfer Services.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC), platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon's first drug candidate, HPN424, is currently in Phase 1 clinical trial as a treatment for prostate cancer.

ZymoGenetics is focused on the discovery, development, and early manufacture of therapeutic proteins. ZymoGenetics is a fully-integrated research and development organization with a broad range of skills and technologies, including scientific computing, molecular and cellular biology, protein chemistry, antibody generation and engineering, clinical development and operations, regulatory affairs, quality, drug formulation, process development and protein manufacturing.

Eli Lilly engages in the discovery, development, manufacture, and sale of products in the pharmaceutical products business segment. The company manufactures and distributes products through owned or leased facilities in the United States, Puerto Rico, and 25 other countries. Its products are sold in approximately 135 countries. It also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Concortis is a biotechnology company creating next generation biotherapeutics using their proprietary conjugation technologies and novel drug delivery systems, which allow them to build small molecule drugs into a variety of biologics with enhanced efficacies and reduced side-effects. The company focuses on oncology and metabolic diseases.

Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.